Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023

January 4, 2024

https://www.globenewswire.com/news-release/2024/01/04/2804369/0/en/Axogen-Reports-Preliminary-Unaudited-Revenue-for-Fourth-Quarter-and-Full-Year-2023.html

ALACHUA, Fla. and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2023 revenue.

Read more at globenewswire.com

Related news for (AXGN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.